DDInter8 DDInter1376
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Abiraterone {u} (Compound) resembles {v} (Compound) Testosterone
Abiraterone {u} (Compound) treats {v} (Disease) prostate cancer
Abiraterone {u} (Compound) binds {v} (Gene) ABCC1
Abiraterone {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Torasemide
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Abiraterone (Compound) resembles Testosterone (Compound)
Abiraterone (Compound) treats prostate cancer (Disease)
Abiraterone (Compound) binds ABCC1 (Gene)
Abiraterone (Compound) causes Hypokalaemia (Side Effect)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Torasemide
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Abiraterone may lead to a major life threatening interaction when taken with Dofetilide
Abiraterone may lead to a major life threatening interaction when taken with Ivabradine